US phase II trial starts for MRA contrast agent:
This article was originally published in Clinica
Advanced Magnetics has begun a phase II clinical trial in the US to test its investigational contrast agent in MR angiography (MRA). The agent, currently known as Code 7228 is a coated iron oxide product. The Cambridge, Massachusetts-based company says that preliminary results concerning the agent's safety profile and blood pool persistence - two critical elements in evaluating cardiovascular imaging agents - suggest that the product shows promise for use in cardiovascular imaging applications such as MRA.